Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18633398 | 1.00 | DDB1 (0.30) | DDB1CRBN | |
| SCHEMBL15357895 | 0.81 | — | — | |
| SCHEMBL2736836 | 0.81 | DDB1 (0.30) | DDB1CRBN | |
| SCHEMBL4954692 | 0.65 | — | — | |
| SCHEMBL1106707 | 0.63 | TSHR (0.32) | — | |
| SCHEMBL1161986 | 0.59 | — | — | |
| SCHEMBL1106712 | 0.56 | — | — | |
| SCHEMBL31310637 | 0.53 | — | — | |
| SCHEMBL9826257 | 0.52 | CRBN (0.33) | DDB1CRBN | |
| SCHEMBL548282 | 0.51 | MAOA (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005068410-A1 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | claimed |
| JP-2004532799-A | — | — | 2004-10-28 | — | — | JP | claimed |
| JP-2004529069-A | — | — | 2004-09-24 | — | — | JP | claimed |
| EP-1363879-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-11-26 | — | — | EP | claimed |
| EP-1351916-A2 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-10-15 | — | — | EP | claimed |
| WO-2002030884-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| WO-2002030863-A2 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| US-11744816-B2 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | ESPERION THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230210800-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20210395175-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20210361605-A1 | FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND EZETIMIBE AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE | GLAS AMERICAS LLC | 2021-11-25 | — | — | US | disclosed |
| US-20210322375-A1 | COMBINATION DRUG FORMULATIONS FOR TREATING PATIENTS WITH CARDIOVASCULAR DISEASE AND ASSOCIATED CONDITIONS | ESPERION THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-10941095-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20080064661-A1 | Tetramethyltetradecanetetraols as anticarcinogenic, anticholesterol, antidiabetic and hypotensive agents; metabolic disorders, peroxisome proliferator activated receptor associated disorder, Alzheimer's Disease, obesity, pancreatitis; increased HDL levels and lowers LDL levels; combination therapy | ESPERION THERAPEUTICS, INC. | 2008-03-13 | — | — | US | disclosed |
| US-7335689-B2 | for example, 6,9-Dihydroxy-2,2,13,13-tetramethyl-tetradecanedioic acid, 2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol, 6,10-Dihydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid; treatment of Alzheimer's Disease, metabolic syndrome disorder, cancer, cardiovascular disease, diabetic nephropathy | ESPERION THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335799-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7304093-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070179120-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | ESPERION THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070155704-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | DASSEUX JEAN-LOUIS H | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941095-B2 | Hydroxyl compounds and compositions for cholesterol management and related uses | NR1H3, CYP27A1, NR1H2 | DDB1 3546/4885CRBN 3099/4885 |
| US-11744816-B2 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | APOB, PCSK9, GOT2 | DDB1 3032/4885CRBN 2892/4885 |
| US-20210395175-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | NR1H3, CYP27A1, NR1H2 | DDB1 3546/4885CRBN 3099/4885 |
| US-20070155704-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | DDB1 2180/4885CRBN 1336/4885 |
| US-20230210800-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | CYP27A1, NR1H3, PNLIP | DDB1 3576/4885CRBN 3255/4885 |
| US-20210361605-A1 | FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND EZETIMIBE AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE | APOB, PCSK9, GOT2 | DDB1 3032/4885CRBN 2892/4885 |
| US-20080064661-A1 | Tetramethyltetradecanetetraols as anticarcinogenic, anticholesterol, antidiabetic and hypotensive agents; metabolic disorders, peroxisome proliferator activated receptor associated disorder, Alzheimer's Disease, obesity, pancreatitis; increased HDL levels and lowers LDL levels; combination therapy | PNLIP, APOL1, NR1H3 | DDB1 1673/4885CRBN 4016/4885 |
| US-20070179120-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | PNLIP, NR1H3, CYP27A1 | DDB1 2518/4885CRBN 3897/4885 |
| US-20210322375-A1 | COMBINATION DRUG FORMULATIONS FOR TREATING PATIENTS WITH CARDIOVASCULAR DISEASE AND ASSOCIATED CONDITIONS | APOB, PCSK9, ECHS1 | DDB1 3915/4885CRBN 3640/4885 |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, GPR119 | DDB1 2180/4885CRBN 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.